MedTrace Logo

The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients

NCT02234492 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2018-10-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether the use of rosuvastatin in Human Immunodeficiency Virus (HIV) infected individuals lowers inflammation in blood vessels, improves blood circulation in the small arteries that provide nutrients to the heart muscle and improves neurocognitive function.

Conditions

  • Human Immunodeficiency Virus (HIV)
  • Cardiovascular Disease (CVD)

Interventions

DRUG

Rosuvastatin

Comparison of rosuvastatin to no rosuvastatin

Sponsors & Collaborators

  • Ontario HIV Treatment Network

    collaborator NETWORK

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Girish Dwivedi, MD MRCP PhD · University of Ottawa Heart Institute, Harry Perkins Institute of Medical Research

  • Gary Small, MD MRCP · Ottawa Heart Institute Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02234492 on ClinicalTrials.gov